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modified PTVs were overlaid and compared on each of the 
diagnostic, planning and verification scans, and coverage of 
tumour classified as well covered, borderline or not covered. 
Our second approach involved forming an ITV as a composite 
volume of the uterus on the bladder full and bladder empty 
scans. Isotropic expansions of 7, 10, 12 and 15mm were then 
applied to determine if a composite PTV would consistently 
encompass the target on CBCT images. 
Results: A total of 40 CBCT images were reviewed for 11 
patients. The unmodified PTV did not fully cover the target in 
16/40 scans (40%) and on at least one scan in 6/11 patients 
(55%). Modified PTV’s provided full coverage on every scan 
but one (98% coverage) in which the bladder volume was 
overfilled (200% volume) compared to the planning scan. 
Isotropic expansions of 10mm and 12mm to the ITV provided 
adequate coverage on 37/40 and 39/40 CBCT’s respectively. 
The composite PTV offered reduced or comparable treated 
volumes to the manually modified PTV. 
Conclusions: A standard CTV-PTV margin does not ensure 
adequate target coverage. It is important to use bladder 
status to predict uterine motion but an additional margin is 
also required due to the impact of rectal filling and tumour 
regression. We recommend forming a composite CTV from 
'bladder empty' and 'bladder full' imaging with a 10 or 12mm 
PTV expansion to ensure an optimal balance between 
adequate coverage and minimisation of normal tissue 
toxicity.  
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Purpose/Objective: To compare treatment fields localised 
between radiographers and clinicians, to investigate if there 
is parity between them. Critically analyse geographical 
variations that exist and assess the subsequent feasibility and 
impact of a radiographer led service. 
Materials and Methods: 23 patients with metastatic spinal 
cord compression (MSCC) were prospectively sampled and 
once a field to treat the patient had been approved by a 
clinician, the CT data set was anonymised. 4 different 
radiographers not involved in the original planning performed 
a localisation for each patient. This gave a total of 92 
localisations to be compared to the clinicians approved 
fields. Agreement between a radiographer and clinician was 
defined as ≤0.5cm between field length, width and 3 
isocentre coordinates. If any one of the five parameters was 
greater than this tolerance, the localisation was not in 
agreement. The primary end point in this study was to 
investigate whether agreement between radiographer and 
clinician was achieved in minimum of 97% of the 
localisations. A secondary end point was to assess the patient 
pathway efficiency and the potential time that could be 
saved with a radiographer led approach. 
Results: 90/92 localisations showed parity therefore the rate 
of agreement between radiographers and clinicians in the 
localisation of radiotherapy fields for MSCC was 97.8% under 
the 0.5cm tolerance defined. In all of the measurable 
parameters, the average differences were less that 0.2cm 
such that there was a statistically significant difference in 
the data from the 0.5cm median (p<0.0001) that would 
establish no agreement between clinician and radiographer. 
Therefore robust parity between the two groups was 
established. An average delay in waiting for a clinician to 
approve the original field was 54 minutes (median and range 
were 48 and 141 minutes respectively).  
Conclusions; A very strong rate of agreement has been 
established along with minimal geographical or geometric 
differences in the localised fields. It has also been 
highlighted that considerable time could be saved in the 
patient’s pathway by removing the need to wait for clinician 
approval of the treatment field. By conducting this study, 
evidence has been collected that has enabled inferences to 
be drawn that a radiographer led service for the localisation 
of MSCC is a feasible option for improving the associated 
pathway and subsequent patient experience. 
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Purpose/Objective: This study examined the radiation doses 
delivered to salivary apparatus in patients receiving intensity 
modulated radiotherapy (IMRT) to the H&N over the past 7 
years. It examined the efficacy of parotid sparing, the effects 
of radiation dose to the submandibular glands (SMGs), minor 
and sublingual salivary glands on the incidence and severity 
of subjective xerostomia and investigated the quality of life 
of surviving patients. 
Materials and Methods: 7 years of retrospective dosimetric 
data were assessed based on the plans of surviving H&N 
cancer patients that were treated by IMRT. SMGs and a new 
surrogate contour representing the minor oral and sublingual 
tissue target (MOIST) were outlined. Doses received by the 
salivary apparatus were statistically analysed in conjunction 
with the EORTC QLQ-C30 and H&N35 module results which 
was completed by participants. 
Results: Mean global QoL was 66.6 out of 100. Emotional 
functioning had the lowest scores amongst the functional 
scales and physical functioning ranked the highest. The 
results of the questionnaire were compared according to sex, 
age and staging. There were no significant differences in any 
of the scores of males and females who completed the EORTC 
QLQ-C30. Regarding age, a statistically significant difference 
in physical functioning score across four different age groups 
(<50 years: n = 4, 50 – 59 years: n = 10, 60- 69 years: n = 20, 
>70 years: n = 7), p =.034 was identified. Significant 
differences in the physical functioning level, p=.024, fatigue 
symptoms, p=.006, and pain symptoms, p=.028 of patients 
with early stage disease and those with locally advanced 
disease were observed. 
Patient global QoL scores were not significantly different to 
scores of a normal population after IMRT. Global QoL scores 
were not influenced by gender, stage or treatment modalities 
in conjunction with IMRT. Dry mouth was the most prevalent 
symptom. Dry mouth scores were not influenced by gender, 
stage or the addition of different treatment modalities such 
as chemotherapy or surgery. There was a moderate and 
statistically significant relationship between xerostomia score 
and global QoL, R = -.428, N=39, p<0.01. Mean dose to the 
salivary apparatus was not correlated with subjective 
xerostomia. Mean dose to the salivary apparatus was not 
shown to have an impact on severity of subjective 
xerostomia. Mean dose to the individual salivary glands was 
not correlated with global QoL scores 
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Conclusions: No significant relationship between the mean 
dose to the salivary apparatus and subjective xerostomia was 
observed. However, this study did show that despite 
undergoing parotid sparing IMRT, a large number of patients 
still display a high degree of symptomology for years after 
treatment, but these symptoms do not appear to have a 
deleterious effect on quality of life in survivors. Patients’ 
perceptions are subject to change after a diagnosis of H&N 
cancer. This study strongly suggests that a psychological 
adjustment of patients to their symptoms and a redefinition 
of their expectations is possible.  
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Recently the first replicated genetic associations and GWAS 
for adverse reactions to radiotherapy have been reported. 
These will help to build predictive statistical models for 
optimising radiotherapy delivery or interventions to alleviate 
the side effects. It is now important to validate known 
predictors of adverse reactions and develop the statistical 
models to become clinically useful. The REQUITE project is a 
European Union funded FP7 project that aims to do this. 
REQUITE’s objectives: 
1. Perform a multi-centre, cohort study collecting: blood 
samples, epidemiology and treatment data, longitudinal side-
effect and QOL data (before and after treatment, years 1 & 
2). 
2. Produce a centralised biobank of DNA from 5,300 patients 
with centralised data management. 
3. Validate published biomarkers of radiosensitivity. 
4. Validate clinical predictors of radiotherapy toxicity in 
breast, prostate and lung cancer and incorporate biomarker 
data. 
5. Design interventional trials to reduce long-term side-
effects. 
6. Provide a resource for dissemination and exploitation to 
the radiotherapy community. 
REQUITE is funded for 60 months from October 2013 and 
organised into seven work packages. WP1 is responsible for 
overall management and scientific oversight run by 
Manchester. The central activity of the project is a multi-
centre, observational study organised through WP2, led by 
DKFZ. Enrolment began in April 2014 and will proceed for 2 
years in nine clinical centres, with 2 years follow-up. Current 
recruitment has exceeded 500 patients. The primary 
endpoints are change in breast appearance; rectal bleeding 
(prostate); pneumonitis (lung). The integrated database has 
been designed at Leicester. 
Blood samples are being collected before radiotherapy. 
Tracking, biobanking and DNA preparation is handled in WP3 
at CIGMR in Manchester. Validation of biomarkers (genetic 
markers and apoptosis assays) as predictive factors is being 
carried out in WP4 led by Leicester. Preliminary work has 
reduced inter-laboratory variation in the FACS-based 
apoptosis assay between Leicester, Mannheim and 
Montpellier. The assay is now being carried out on all samples 
collected through the three centres. The data will establish 
whether the assay can be used as a standard test to predict 
radiotherapy toxicity. 
In WP5 Gent is leading in validating published models in 
existing cohorts, leading to replicated models that can be 
validated using the REQUITE cohorts. In WP6 Leuven will use 
the predictive models to design clinical interventional trials 
and produce protocols that seek to lower radiotherapy side-
effects in those individuals at high risk of developing them 
without affecting tumour control. Dissemination and 
Outreach is being co-ordinated through WP7 led by MAASTRO. 
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Biomarkers of normal tissue toxicity are used in determining 
predictive models of toxicity and may help understanding of 
the biology of radiation response in normal tissue. 
Whilst clinical assessment of toxicity has been evaluated 
quantitatively, this often encompasses complex clinical 
endpoints, incorporating different pathological entities. 
Other quantitative assessments of normal tissue effects 
which may more directly reflect underlying pathological 
alterations in tissue include imaging at the anatomical or 
functional level, and measurement of cell or molecular 
alterations in blood or tissue. These approaches may improve 
descriptive radiobiology or the characterization of late 
normal tissue effects. 
